主页 > 医学文档 >
【medical-news】首次HIV基因治疗结果让人兴奋（s
First HIV Gene Therapy Test Encouraging
By RANDOLPH E. SCHMID
The Associated Press
Monday, November 6, 2006; 6:19 PM
WASHINGTON -- The first test of a potential new gene therapy for HIV _ the virus that causes AIDS _ was encouraging enough for researchers to launch a more extensive trial.
"The goal of this phase I trial was safety and feasibility, and the results established that," said lead researcher Dr. Carl June. "But the results also hint at something much more."
The first test of a potential new gene therapy for HIV _ the virus that causes AIDS _ was encouraging enough for researchers to launch a more extensive trial. In addition to showing that the treatment was possible and didn't endanger the patients, the amount of virus in the subjects remained steady or decreased during the study, which involved just five people with chronic HIV infection. (AP GRAPHIC) (AP)
Save & Share Article What's This?
DiggGoogle
del.icio.usYahoo!
RedditFacebook
In addition to showing that the treatment was possible and didn't endanger the patients, the amount of virus in the subjects remained steady or decreased during the study, which involved just five people with chronic HIV infection.
One patient had a sustained decrease in the amount of virus, and immune cells and strength of the immune system increased in four patients during the nine-month study.
However, "just because this has produced encouraging results in one or two patients doesn't mean it will work for everyone. We have much more work to do," said co-author Dr. Bruce Levine.
June and Levine are researchers at the University of Pennsylvania's Abramson Family Cancer Research Institute. Their findings are reported in the online edition of Proceedings of the National Academy of Sciences.
The study team also included researchers from the VIRxSYS Corp. of Gaithersburg, Md., which is involved in developing the new treatment and helped fund the study. Other funding came from the National Institutes of Allergy and Infectious Disease and the Abramson institute.
The researchers removed immune cells from the patients and introduced a virus called a lentivirus into the cells. This change prevents HIV from reproducing and, in the laboratory, has the ability to fight HIV in cells that have not been treated, June explained in a telephone interview.
The idea, he said, was that unlike most HIV medications that have to be taken daily or several times a day, this treatment can be done once and will keep fighting the infection.
This was the first human test to see if it could be done safely, he said. It was done on patients whose HIV infections have resisted treatment.
Now, the team has launched a phase II test that will involve more patients, including some whose HIV is controlled by drugs. In this test the patients will get more than one transfusion of the treated cells. Those on standard drug treatment, following the new therapy, will be asked to interrupt their drugs to see if the infection returns.
"This paper should make quite some noise," commented Dr. Martin Haas, a professor at the University of California San Diego School of Medicine.
"I think this is very important work and they have doggedly continued it," said Haas, who was not part of the research team. "I think they have really significant prospects to develop this into serious anti-HIV approaches for those patients in whom HIV cannot be kept under control by chemical means." 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 First HIV Gene Therapy Test Encouraging
首例HIV基因治疗结果让人鼓舞
By RANDOLPH E. SCHMID
The Associated Press
Monday, November 6, 2006; 6:19 PM
美联社通讯员RANDOLPH E.SCHMID
2006年11月6日，星期一，6:19pm
WASHINGTON -- The first test of a potential new gene therapy for HIV _ the virus that causes AIDS _ was encouraging enough for researchers to launch a more extensive trial.
华盛顿消息－－首例HIV（导致艾滋病的病毒）基因治疗新试验让研究人员大受鼓舞并决定开展一个更大规模的试验。
"The goal of this phase I trial was safety and feasibility, and the results established that," said lead researcher Dr. Carl June. "But the results also hint at something much more."
“一期临床试验的目的是验证安全性和可行性，我们的结果已经证实了这一点，”首席研究员Carl June博士说，“而且我们的结果提示了更多。”
In addition to showing that the treatment was possible and didn't endanger the patients, the amount of virus in the subjects remained steady or decreased during the study, which involved just five people with chronic HIV infection.
除了表明这一治疗方法是可行而且安全的，在该研究中，受试者的病毒水平保持稳定或者下降，虽然该研究只涉及5名慢性HIV感染者。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-10-28 17:11
医学,生命科学网